Meeting
2013 ASCO Annual Meeting
Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma.
Authors
Mark Andrew Dickson
Memorial Sloan-Kettering Cancer Center, New York, NY
Mark Andrew Dickson , Michelle R. Mahoney , Benjamin T. Marchello , Mercedes M. Condy , William D. Tap , Gary K. Schwartz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01653028
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS10594)
DOI
10.1200/jco.2013.31.15_suppl.tps10594
Abstract #
TPS10594
Poster Bd #
51D
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
First Author: Mark Andrew Dickson
Poster
2022 ASCO Annual Meeting
Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.
First Author: Neha Mehta-Shah
Poster
2016 ASCO Annual Meeting
Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL).
First Author: Kunihiro Tsukasaki
Poster
2015 ASCO Annual Meeting
Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).
First Author: Melissa K. Yee